Global incidence of young-onset dementia: A systematic review and meta-analysis

Stevie Hendriks, Kirsten Peetoom, Young-Onset Dementia Epidemiology Study Group, Christian Bakker, Raymond Koopmans, Wiesje van der Flier, Janne Papma, Frans Verhey, Marjolein de Vugt, Sebastian Köhler*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Citations (Scopus)
213 Downloads (Pure)

Abstract

Introduction: Reliable data on the incidence rates for young-onset dementia (YOD) are lacking, but are necessary for research on disease etiology and to raise awareness among health care professionals. Methods: We performed a systematic review and meta-analysis on population-based studies on the incidence of YOD, published between January 1, 1990 and February 1, 2022, according to Meta-analyses of Observational Studies in Epidemiology (MOOSE) guidelines. Data were analyzed using random-effects meta-analyses. Results were age-standardized, and heterogeneity was assessed by subgroup analyses and meta-regression. Results: Sixty-one articles were included. Global age-standardized incidence rates increased from 0.17/100,000 in age 30 to 34 years, to 5.14/100,000 in age 60 to 64 years, giving a global total age-standardized incidence rate of 11 per 100,000 in age 30 to 64. This corresponds to 370,000 new YOD cases annually worldwide. Heterogeneity was high and meta-regression showed geographic location significantly influenced this heterogeneity. Discussion: This meta-analysis shows the current best estimate of YOD incidence. New prospective cohort studies are needed.

Original languageEnglish
Pages (from-to)831-843
Number of pages13
JournalAlzheimer's and Dementia
Volume19
Issue number3
Early online date17 Jun 2022
DOIs
Publication statusPublished - Mar 2023

Bibliographical note

Funding Information:
Stevie Hendriks, Kirsten Peetoom, Christian Bakker, Raymond Koopmans, Janne Papma Wiesje Van der Flier, Frans Verhey, Marjolein de Vugt, and Sebastian Köhler received support for the present manuscript from Gieskes‐Strijbis Foundation, Alzheimer Netherlands, and Dutch Knowledge Centre on Young‐Onset Dementia. All funding was paid to the institutions. Research programs of Wiesje van der Flier have been funded by ZonMW, NOW, EU‐FP7, EU‐JPND, Alzheimer Netherlands, CardioVascular Onderzoek Nederland, Health‐Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis Foundation, stichting Equilibrio, Pasman stichting, Biogen MA Inc, Boehringer Ingelheim, Life‐MI, AVID, Roche BV, Fujifilm, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public‐private partnership receiving funding from ZonMW (#73305095007) and Health‐Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). All funding is paid to her institution. Research programs of Janne Papma have been funded by ZonMW, Alzheimer Netherlands. All funding is paid to her institution. Research programs of Marjolein de Vugt have been funded by ZonMW, Gieskes‐Strijbis Foundation, Alzheimer Netherlands, and Hersenstichting. Funding is paid to her institution. Wiesje van der Flier is consultant of Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. All funding is paid to her institution. Wiesje van der Flier has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, and WebMD Neurology (Medscape). All funding is paid to her institution. Janne Papma has been paid once for a lecture on a scientific meeting (TN2 Amsterdam). Wiesje van der Flier participated in an advisory board of Biogen MA Inc. All funding is paid to her institution. Frans Verhey participated in two meetings of 2 hours each with Biogen to discuss the impact of their product. All funding is paid to his institution. Christian Bakker holds an unpaid position in the board of the Dutch Knowledge Centre on Young‐Onset Dementia. Wiesje van der Flier was associate editor at in 2020/2021. WF is associate editor at . All funding is paid to her institution. Marjolein de Vugt is a board member of the European INTERDEM network (unpaid). Author disclosures are available in the supporting information . Alzheimer, Research & Therapy Brain

Funding Information:
The authors would like to thank the PRECODE‐project team for their suggestions and collaboration. Funding for this article was provided by the Gieskes‐Strijbis Foundation, Alzheimer Netherlands, and the Dutch Young‐Onset Dementia Knowledge Centre. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Funding Information:
The authors would like to thank the PRECODE-project team for their suggestions and collaboration. Funding for this article was provided by the Gieskes-Strijbis Foundation, Alzheimer Netherlands, and the Dutch Young-Onset Dementia Knowledge Centre. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Publisher Copyright:
© 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Fingerprint

Dive into the research topics of 'Global incidence of young-onset dementia: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this